Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 291-296

  Zizzo, Nicola ^a   Patruno, Rosa ^a,b   Zito, Francesco Alfredo ^b   Summa, Aldo Di ^a   Tinelli, Antonella ^a   Troilo, Sante ^c   Misino, Andrea ^b   Ruggieri, Eustachio ^b   Goffredo, Veronica ^b   Gadaleta, Cosmo Damiano ^b   Ranieri, Girolamo ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c ASL Bari   (Italy)

Author keywords

Angiogenesis; Canine non Hodgkin lymphoma; ELISA; Immunohistochemistry; Platelets; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MODEL; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; B-LYMPHOCYTES; BLOOD PLATELETS; CYTOSOL; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-RICH PLASMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76349090234     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903452818     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:209-215.
2. Patruno R, Arpaia N, Gadaleta CD, et al. VEGF concentration from plasma activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 2009;13:555-561.
3. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
4. Ranieri G, Grammatica L, Patruno R, et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J CellMol Med 2007;11:362-368.
5. Kato Y, Asano K, Mogi T, et al. Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors. J Vet Med Sci 2007;69:77-80.
6. Wergin MC, Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 2004;18:15-19.
7. Ranieri G, Coviello M, Chiriatti A, et al. Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep 2004;11:435-439.
8. Ranieri G, Coviello M, Patruno R, et al. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 2004;2:817-820.
9. Clifford CA, Hughes D, Beal MW, et al. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med 2001;15:131-135.
10. Hormbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002;19:651-663.
11. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Lab Invest 2002;62:343-350.
12. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487-491.
13. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13:5341-5347.
14. Verheul HMW, Hoekman K, de Bakker SL, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-2190.
15. Gentilini F, Calzolari C, Turba ME, et al. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leuk Res 2005;29:1263-1269.
16. Ranieri G, Patruno R, Lionetti A, et al. Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma 2005;46:1639-1643.
17. Hazar B, Paydas Z, Zorludemir S, Sahin S, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non- Hodgkin's lymphoma. Leuk Lymphoma 2003;44:2089-2093.
18. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999;79:965-970.
19. Patruno R, Zizzo N, Zito AF, et al. Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model. Leuk Lymphoma 2006;47:1138-1143.
20. Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 1995;20:27-38.
21. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non- Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996;56:45-53.
22. Troy GC, Huckle WR, Rossmeisl JH, et al. Endostatin and vascular endothelial growth factor concentrations in healthy dogs, dogs with selected neoplasia, and dogs with nonneoplastic diseases. J Vet Intern Med 2006;20:144-150.
23. Fournel-Fleury C, Ponce F, Felman P, et al. Canine T-cell lymphomas: a morphological, immunological, and clinical study of 46 new cases. Vet Pathol 2002;39:92-109.
24. Ferre L, Fondeila D, Rabanal R, Ramis A. Detection of T lymphocytes in canine tissue embedded in paraffin wax by means of antiboby to CD-3antigen. J Comp Path 1992;106: 311-314.
25. Ranieri G, Passantino L, Patruno R, et al. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep 2003;10:1189-1193.
26. Ranieri G, Gasparini G. Surrogate markers of angiogenesis and metastasis. In: Brooks S, editor. Metastasis research protocols. Oxford: Humana Press; 2001. pp 99-114.
27. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845-1857.
28. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006; 12:7444-7455.
29. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001;47:617-623.
30. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964.
31. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007;97:978-985.
32. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood 2009;113:2835-2842.
33. Ria R, Cirulli T, Giannini T, Bambace S, et al. Serum levels of angiogenic cytokines decrease after radiotherapy in non- Hodgkin lymphomas. Clin Exp Med 2008;8:141-145.
34. Etto L, Lacerda E, Baiocchi O, et al. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:257-264.
35. Passam FH, Sfiridaki A, Pappa C, et al. Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol 2008;30:17-25.
36. Gentilini F, Calzolari C, Turba ME, et al. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leuk Res 2005;29:1263-1269.
37. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000;96:3712-3718.
38. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008;8:301-314.